Nat Commun:lncRNA HOXBLINC促进NPM1突变的急性髓性白血病的发生

2021-04-02 xiaozeng MedSci原创

NPM1是急性髓细胞性白血病(AML)中最常见的突变基因,约有50%的成年和20%的儿童AML患者发生该基因的突变。

NPM1是急性髓细胞性白血病(AML)中最常见的突变基因,约有50%的成年和20%的儿童AML患者发生该基因的突变。NPM1编码的蛋白质通常位于核仁中,并参与了多种生物学功能,包括核糖体的生物合成和基因组稳定性的维持。

NPM1突变导致突变蛋白(NPM1c+)发生错误的胞质定位,这也对其在白血病发生中的作用至关重要。NPM1c+能够维持独特的白血病基因表达程序,其特征在于激活HOXA/B簇和MEIS1癌基因,并促进了白血病的发生。然而,NPM1c+驱动白血病基因表达程序的确切机制仍不清楚。

在该研究中,研究人员发现,长非编码RNA(lncRNA) HOXBLINC的激活是NPM1c+相关的白血病转录程序和白血病发生的关键下游介质。HOXBLINC缺失可通过纠正NPM1c+白血病的转录程序来减弱NPM1c+驱动的白血病发生。

HOXBLINC在NPM1c+AML患者中被激活

此外,在小鼠模型中过表达HoxBlinc(HoxBlincTg)能够增强造血干细胞(HSC)的自我更新能力,并增强骨髓的生成,从而导致了AML样疾病的发生。HoxBlincTg和Npm1c/+(Npm1突变型)HSPC(造血干/祖细胞)具有明显重叠的转录组和染色质结构。

过表达HoxBlinc诱导小鼠AML的发生

机制研究显示,HoxBlinc通过招募NLL1,结合NPM1c+相关基因的启动子区域并进行H3K4me3修饰,从而调控这些基因在HoxBlincTg HSPC中的激活。


总而言之,该研究表明,lncRNA HOXBLINC的激活在NPM1c+白血病中起着重要的致癌作用。而HOXBLINC和MLL1是NPM1c+AML的潜在治疗靶标。


原始出处:

Zhu, G., Luo, H., Feng, Y. et al. HOXBLINC long non-coding RNA activation promotes leukemogenesis in NPM1-mutant acute myeloid leukemia. Nat Commun 12, 1956 (29 March 2021).

 

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (16)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=2005751, encodeId=64c42005e51b4, content=<a href='/topic/show?id=6ff1525e13' target=_blank style='color:#2F92EE;'>#CRN#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5257, encryptionId=6ff1525e13, topicName=CRN)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=35fc2500023, createdName=yanjie6253_56072842, createdTime=Fri Feb 25 03:52:37 CST 2022, time=2022-02-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2087964, encodeId=6b6e208e96406, content=<a href='/topic/show?id=490750196b' target=_blank style='color:#2F92EE;'>#COMMUN#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5019, encryptionId=490750196b, topicName=COMMUN)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7931272, createdName=liuli5079, createdTime=Sat Apr 10 05:52:37 CST 2021, time=2021-04-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1885082, encodeId=3d4918850825e, content=<a href='/topic/show?id=3b2112532d8' target=_blank style='color:#2F92EE;'>#Nat#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12532, encryptionId=3b2112532d8, topicName=Nat)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2e6f107, createdName=liye789132251, createdTime=Wed Mar 16 16:52:37 CST 2022, time=2022-03-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=953397, encodeId=5b1695339e43, content=lncRNA HOXBLINC的激活在NPM1c+白血病中起着重要的致癌作用。<a href='/topic/show?id=1991e1775c9' target=_blank style='color:#2F92EE;'>#白血病#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=160, replyNumber=1, topicName=null, topicId=null, topicList=[TopicDto(id=71775, encryptionId=1991e1775c9, topicName=白血病)], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210725/69b5882b3c3845c19efa131b4ff8b1f7/06ccd8f1857e4e14862049ab235618eb.jpg, createdBy=74c72110107, createdName=Nebula-Qin, createdTime=Fri Apr 02 23:14:07 CST 2021, time=2021-04-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1974523, encodeId=987a19e4523b5, content=<a href='/topic/show?id=e37b144015f' target=_blank style='color:#2F92EE;'>#PM1#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14401, encryptionId=e37b144015f, topicName=PM1)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d2f42500210, createdName=12498ef1m31(暂无昵称), createdTime=Thu Sep 09 13:52:37 CST 2021, time=2021-09-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=953781, encodeId=d646953e81df, content=棒棒哒, beContent=null, objectType=article, channel=null, level=null, likeNumber=73, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7c151583732, createdName=446993560, createdTime=Sun Apr 04 17:18:12 CST 2021, time=2021-04-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=953651, encodeId=f08895365176, content=写的不错, beContent=null, objectType=article, channel=null, level=null, likeNumber=77, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7c151583732, createdName=446993560, createdTime=Sat Apr 03 21:34:59 CST 2021, time=2021-04-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1301946, encodeId=0f781301946bb, content=<a href='/topic/show?id=b469109e41d' target=_blank style='color:#2F92EE;'>#lncRNA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=46, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10974, encryptionId=b469109e41d, topicName=lncRNA)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2317301, createdName=xzw113, createdTime=Sat Apr 03 15:52:37 CST 2021, time=2021-04-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1514486, encodeId=abc415144867b, content=<a href='/topic/show?id=1ae010211143' target=_blank style='color:#2F92EE;'>#髓性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=102111, encryptionId=1ae010211143, topicName=髓性)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ae8810654266, createdName=more is better!, createdTime=Sat Apr 03 15:52:37 CST 2021, time=2021-04-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1553765, encodeId=0da31553e6572, content=<a href='/topic/show?id=5d56130069b' target=_blank style='color:#2F92EE;'>#NPM1#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=46, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13006, encryptionId=5d56130069b, topicName=NPM1)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=778d36, createdName=柳叶一刀, createdTime=Sat Apr 03 15:52:37 CST 2021, time=2021-04-03, status=1, ipAttribution=)]
  2. [GetPortalCommentsPageByObjectIdResponse(id=2005751, encodeId=64c42005e51b4, content=<a href='/topic/show?id=6ff1525e13' target=_blank style='color:#2F92EE;'>#CRN#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5257, encryptionId=6ff1525e13, topicName=CRN)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=35fc2500023, createdName=yanjie6253_56072842, createdTime=Fri Feb 25 03:52:37 CST 2022, time=2022-02-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2087964, encodeId=6b6e208e96406, content=<a href='/topic/show?id=490750196b' target=_blank style='color:#2F92EE;'>#COMMUN#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5019, encryptionId=490750196b, topicName=COMMUN)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7931272, createdName=liuli5079, createdTime=Sat Apr 10 05:52:37 CST 2021, time=2021-04-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1885082, encodeId=3d4918850825e, content=<a href='/topic/show?id=3b2112532d8' target=_blank style='color:#2F92EE;'>#Nat#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12532, encryptionId=3b2112532d8, topicName=Nat)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2e6f107, createdName=liye789132251, createdTime=Wed Mar 16 16:52:37 CST 2022, time=2022-03-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=953397, encodeId=5b1695339e43, content=lncRNA HOXBLINC的激活在NPM1c+白血病中起着重要的致癌作用。<a href='/topic/show?id=1991e1775c9' target=_blank style='color:#2F92EE;'>#白血病#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=160, replyNumber=1, topicName=null, topicId=null, topicList=[TopicDto(id=71775, encryptionId=1991e1775c9, topicName=白血病)], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210725/69b5882b3c3845c19efa131b4ff8b1f7/06ccd8f1857e4e14862049ab235618eb.jpg, createdBy=74c72110107, createdName=Nebula-Qin, createdTime=Fri Apr 02 23:14:07 CST 2021, time=2021-04-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1974523, encodeId=987a19e4523b5, content=<a href='/topic/show?id=e37b144015f' target=_blank style='color:#2F92EE;'>#PM1#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14401, encryptionId=e37b144015f, topicName=PM1)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d2f42500210, createdName=12498ef1m31(暂无昵称), createdTime=Thu Sep 09 13:52:37 CST 2021, time=2021-09-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=953781, encodeId=d646953e81df, content=棒棒哒, beContent=null, objectType=article, channel=null, level=null, likeNumber=73, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7c151583732, createdName=446993560, createdTime=Sun Apr 04 17:18:12 CST 2021, time=2021-04-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=953651, encodeId=f08895365176, content=写的不错, beContent=null, objectType=article, channel=null, level=null, likeNumber=77, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7c151583732, createdName=446993560, createdTime=Sat Apr 03 21:34:59 CST 2021, time=2021-04-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1301946, encodeId=0f781301946bb, content=<a href='/topic/show?id=b469109e41d' target=_blank style='color:#2F92EE;'>#lncRNA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=46, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10974, encryptionId=b469109e41d, topicName=lncRNA)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2317301, createdName=xzw113, createdTime=Sat Apr 03 15:52:37 CST 2021, time=2021-04-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1514486, encodeId=abc415144867b, content=<a href='/topic/show?id=1ae010211143' target=_blank style='color:#2F92EE;'>#髓性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=102111, encryptionId=1ae010211143, topicName=髓性)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ae8810654266, createdName=more is better!, createdTime=Sat Apr 03 15:52:37 CST 2021, time=2021-04-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1553765, encodeId=0da31553e6572, content=<a href='/topic/show?id=5d56130069b' target=_blank style='color:#2F92EE;'>#NPM1#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=46, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13006, encryptionId=5d56130069b, topicName=NPM1)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=778d36, createdName=柳叶一刀, createdTime=Sat Apr 03 15:52:37 CST 2021, time=2021-04-03, status=1, ipAttribution=)]
    2021-04-10 liuli5079
  3. [GetPortalCommentsPageByObjectIdResponse(id=2005751, encodeId=64c42005e51b4, content=<a href='/topic/show?id=6ff1525e13' target=_blank style='color:#2F92EE;'>#CRN#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5257, encryptionId=6ff1525e13, topicName=CRN)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=35fc2500023, createdName=yanjie6253_56072842, createdTime=Fri Feb 25 03:52:37 CST 2022, time=2022-02-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2087964, encodeId=6b6e208e96406, content=<a href='/topic/show?id=490750196b' target=_blank style='color:#2F92EE;'>#COMMUN#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5019, encryptionId=490750196b, topicName=COMMUN)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7931272, createdName=liuli5079, createdTime=Sat Apr 10 05:52:37 CST 2021, time=2021-04-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1885082, encodeId=3d4918850825e, content=<a href='/topic/show?id=3b2112532d8' target=_blank style='color:#2F92EE;'>#Nat#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12532, encryptionId=3b2112532d8, topicName=Nat)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2e6f107, createdName=liye789132251, createdTime=Wed Mar 16 16:52:37 CST 2022, time=2022-03-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=953397, encodeId=5b1695339e43, content=lncRNA HOXBLINC的激活在NPM1c+白血病中起着重要的致癌作用。<a href='/topic/show?id=1991e1775c9' target=_blank style='color:#2F92EE;'>#白血病#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=160, replyNumber=1, topicName=null, topicId=null, topicList=[TopicDto(id=71775, encryptionId=1991e1775c9, topicName=白血病)], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210725/69b5882b3c3845c19efa131b4ff8b1f7/06ccd8f1857e4e14862049ab235618eb.jpg, createdBy=74c72110107, createdName=Nebula-Qin, createdTime=Fri Apr 02 23:14:07 CST 2021, time=2021-04-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1974523, encodeId=987a19e4523b5, content=<a href='/topic/show?id=e37b144015f' target=_blank style='color:#2F92EE;'>#PM1#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14401, encryptionId=e37b144015f, topicName=PM1)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d2f42500210, createdName=12498ef1m31(暂无昵称), createdTime=Thu Sep 09 13:52:37 CST 2021, time=2021-09-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=953781, encodeId=d646953e81df, content=棒棒哒, beContent=null, objectType=article, channel=null, level=null, likeNumber=73, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7c151583732, createdName=446993560, createdTime=Sun Apr 04 17:18:12 CST 2021, time=2021-04-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=953651, encodeId=f08895365176, content=写的不错, beContent=null, objectType=article, channel=null, level=null, likeNumber=77, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7c151583732, createdName=446993560, createdTime=Sat Apr 03 21:34:59 CST 2021, time=2021-04-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1301946, encodeId=0f781301946bb, content=<a href='/topic/show?id=b469109e41d' target=_blank style='color:#2F92EE;'>#lncRNA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=46, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10974, encryptionId=b469109e41d, topicName=lncRNA)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2317301, createdName=xzw113, createdTime=Sat Apr 03 15:52:37 CST 2021, time=2021-04-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1514486, encodeId=abc415144867b, content=<a href='/topic/show?id=1ae010211143' target=_blank style='color:#2F92EE;'>#髓性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=102111, encryptionId=1ae010211143, topicName=髓性)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ae8810654266, createdName=more is better!, createdTime=Sat Apr 03 15:52:37 CST 2021, time=2021-04-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1553765, encodeId=0da31553e6572, content=<a href='/topic/show?id=5d56130069b' target=_blank style='color:#2F92EE;'>#NPM1#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=46, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13006, encryptionId=5d56130069b, topicName=NPM1)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=778d36, createdName=柳叶一刀, createdTime=Sat Apr 03 15:52:37 CST 2021, time=2021-04-03, status=1, ipAttribution=)]
    2022-03-16 liye789132251
  4. [GetPortalCommentsPageByObjectIdResponse(id=2005751, encodeId=64c42005e51b4, content=<a href='/topic/show?id=6ff1525e13' target=_blank style='color:#2F92EE;'>#CRN#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5257, encryptionId=6ff1525e13, topicName=CRN)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=35fc2500023, createdName=yanjie6253_56072842, createdTime=Fri Feb 25 03:52:37 CST 2022, time=2022-02-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2087964, encodeId=6b6e208e96406, content=<a href='/topic/show?id=490750196b' target=_blank style='color:#2F92EE;'>#COMMUN#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5019, encryptionId=490750196b, topicName=COMMUN)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7931272, createdName=liuli5079, createdTime=Sat Apr 10 05:52:37 CST 2021, time=2021-04-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1885082, encodeId=3d4918850825e, content=<a href='/topic/show?id=3b2112532d8' target=_blank style='color:#2F92EE;'>#Nat#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12532, encryptionId=3b2112532d8, topicName=Nat)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2e6f107, createdName=liye789132251, createdTime=Wed Mar 16 16:52:37 CST 2022, time=2022-03-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=953397, encodeId=5b1695339e43, content=lncRNA HOXBLINC的激活在NPM1c+白血病中起着重要的致癌作用。<a href='/topic/show?id=1991e1775c9' target=_blank style='color:#2F92EE;'>#白血病#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=160, replyNumber=1, topicName=null, topicId=null, topicList=[TopicDto(id=71775, encryptionId=1991e1775c9, topicName=白血病)], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210725/69b5882b3c3845c19efa131b4ff8b1f7/06ccd8f1857e4e14862049ab235618eb.jpg, createdBy=74c72110107, createdName=Nebula-Qin, createdTime=Fri Apr 02 23:14:07 CST 2021, time=2021-04-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1974523, encodeId=987a19e4523b5, content=<a href='/topic/show?id=e37b144015f' target=_blank style='color:#2F92EE;'>#PM1#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14401, encryptionId=e37b144015f, topicName=PM1)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d2f42500210, createdName=12498ef1m31(暂无昵称), createdTime=Thu Sep 09 13:52:37 CST 2021, time=2021-09-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=953781, encodeId=d646953e81df, content=棒棒哒, beContent=null, objectType=article, channel=null, level=null, likeNumber=73, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7c151583732, createdName=446993560, createdTime=Sun Apr 04 17:18:12 CST 2021, time=2021-04-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=953651, encodeId=f08895365176, content=写的不错, beContent=null, objectType=article, channel=null, level=null, likeNumber=77, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7c151583732, createdName=446993560, createdTime=Sat Apr 03 21:34:59 CST 2021, time=2021-04-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1301946, encodeId=0f781301946bb, content=<a href='/topic/show?id=b469109e41d' target=_blank style='color:#2F92EE;'>#lncRNA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=46, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10974, encryptionId=b469109e41d, topicName=lncRNA)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2317301, createdName=xzw113, createdTime=Sat Apr 03 15:52:37 CST 2021, time=2021-04-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1514486, encodeId=abc415144867b, content=<a href='/topic/show?id=1ae010211143' target=_blank style='color:#2F92EE;'>#髓性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=102111, encryptionId=1ae010211143, topicName=髓性)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ae8810654266, createdName=more is better!, createdTime=Sat Apr 03 15:52:37 CST 2021, time=2021-04-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1553765, encodeId=0da31553e6572, content=<a href='/topic/show?id=5d56130069b' target=_blank style='color:#2F92EE;'>#NPM1#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=46, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13006, encryptionId=5d56130069b, topicName=NPM1)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=778d36, createdName=柳叶一刀, createdTime=Sat Apr 03 15:52:37 CST 2021, time=2021-04-03, status=1, ipAttribution=)]
    2021-04-02 Nebula-Qin

    lncRNA HOXBLINC的激活在NPM1c+白血病中起着重要的致癌作用。#白血病#

    1

    展开1条回复
  5. [GetPortalCommentsPageByObjectIdResponse(id=2005751, encodeId=64c42005e51b4, content=<a href='/topic/show?id=6ff1525e13' target=_blank style='color:#2F92EE;'>#CRN#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5257, encryptionId=6ff1525e13, topicName=CRN)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=35fc2500023, createdName=yanjie6253_56072842, createdTime=Fri Feb 25 03:52:37 CST 2022, time=2022-02-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2087964, encodeId=6b6e208e96406, content=<a href='/topic/show?id=490750196b' target=_blank style='color:#2F92EE;'>#COMMUN#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5019, encryptionId=490750196b, topicName=COMMUN)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7931272, createdName=liuli5079, createdTime=Sat Apr 10 05:52:37 CST 2021, time=2021-04-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1885082, encodeId=3d4918850825e, content=<a href='/topic/show?id=3b2112532d8' target=_blank style='color:#2F92EE;'>#Nat#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12532, encryptionId=3b2112532d8, topicName=Nat)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2e6f107, createdName=liye789132251, createdTime=Wed Mar 16 16:52:37 CST 2022, time=2022-03-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=953397, encodeId=5b1695339e43, content=lncRNA HOXBLINC的激活在NPM1c+白血病中起着重要的致癌作用。<a href='/topic/show?id=1991e1775c9' target=_blank style='color:#2F92EE;'>#白血病#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=160, replyNumber=1, topicName=null, topicId=null, topicList=[TopicDto(id=71775, encryptionId=1991e1775c9, topicName=白血病)], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210725/69b5882b3c3845c19efa131b4ff8b1f7/06ccd8f1857e4e14862049ab235618eb.jpg, createdBy=74c72110107, createdName=Nebula-Qin, createdTime=Fri Apr 02 23:14:07 CST 2021, time=2021-04-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1974523, encodeId=987a19e4523b5, content=<a href='/topic/show?id=e37b144015f' target=_blank style='color:#2F92EE;'>#PM1#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14401, encryptionId=e37b144015f, topicName=PM1)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d2f42500210, createdName=12498ef1m31(暂无昵称), createdTime=Thu Sep 09 13:52:37 CST 2021, time=2021-09-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=953781, encodeId=d646953e81df, content=棒棒哒, beContent=null, objectType=article, channel=null, level=null, likeNumber=73, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7c151583732, createdName=446993560, createdTime=Sun Apr 04 17:18:12 CST 2021, time=2021-04-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=953651, encodeId=f08895365176, content=写的不错, beContent=null, objectType=article, channel=null, level=null, likeNumber=77, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7c151583732, createdName=446993560, createdTime=Sat Apr 03 21:34:59 CST 2021, time=2021-04-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1301946, encodeId=0f781301946bb, content=<a href='/topic/show?id=b469109e41d' target=_blank style='color:#2F92EE;'>#lncRNA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=46, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10974, encryptionId=b469109e41d, topicName=lncRNA)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2317301, createdName=xzw113, createdTime=Sat Apr 03 15:52:37 CST 2021, time=2021-04-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1514486, encodeId=abc415144867b, content=<a href='/topic/show?id=1ae010211143' target=_blank style='color:#2F92EE;'>#髓性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=102111, encryptionId=1ae010211143, topicName=髓性)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ae8810654266, createdName=more is better!, createdTime=Sat Apr 03 15:52:37 CST 2021, time=2021-04-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1553765, encodeId=0da31553e6572, content=<a href='/topic/show?id=5d56130069b' target=_blank style='color:#2F92EE;'>#NPM1#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=46, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13006, encryptionId=5d56130069b, topicName=NPM1)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=778d36, createdName=柳叶一刀, createdTime=Sat Apr 03 15:52:37 CST 2021, time=2021-04-03, status=1, ipAttribution=)]
  6. [GetPortalCommentsPageByObjectIdResponse(id=2005751, encodeId=64c42005e51b4, content=<a href='/topic/show?id=6ff1525e13' target=_blank style='color:#2F92EE;'>#CRN#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5257, encryptionId=6ff1525e13, topicName=CRN)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=35fc2500023, createdName=yanjie6253_56072842, createdTime=Fri Feb 25 03:52:37 CST 2022, time=2022-02-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2087964, encodeId=6b6e208e96406, content=<a href='/topic/show?id=490750196b' target=_blank style='color:#2F92EE;'>#COMMUN#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5019, encryptionId=490750196b, topicName=COMMUN)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7931272, createdName=liuli5079, createdTime=Sat Apr 10 05:52:37 CST 2021, time=2021-04-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1885082, encodeId=3d4918850825e, content=<a href='/topic/show?id=3b2112532d8' target=_blank style='color:#2F92EE;'>#Nat#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12532, encryptionId=3b2112532d8, topicName=Nat)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2e6f107, createdName=liye789132251, createdTime=Wed Mar 16 16:52:37 CST 2022, time=2022-03-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=953397, encodeId=5b1695339e43, content=lncRNA HOXBLINC的激活在NPM1c+白血病中起着重要的致癌作用。<a href='/topic/show?id=1991e1775c9' target=_blank style='color:#2F92EE;'>#白血病#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=160, replyNumber=1, topicName=null, topicId=null, topicList=[TopicDto(id=71775, encryptionId=1991e1775c9, topicName=白血病)], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210725/69b5882b3c3845c19efa131b4ff8b1f7/06ccd8f1857e4e14862049ab235618eb.jpg, createdBy=74c72110107, createdName=Nebula-Qin, createdTime=Fri Apr 02 23:14:07 CST 2021, time=2021-04-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1974523, encodeId=987a19e4523b5, content=<a href='/topic/show?id=e37b144015f' target=_blank style='color:#2F92EE;'>#PM1#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14401, encryptionId=e37b144015f, topicName=PM1)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d2f42500210, createdName=12498ef1m31(暂无昵称), createdTime=Thu Sep 09 13:52:37 CST 2021, time=2021-09-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=953781, encodeId=d646953e81df, content=棒棒哒, beContent=null, objectType=article, channel=null, level=null, likeNumber=73, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7c151583732, createdName=446993560, createdTime=Sun Apr 04 17:18:12 CST 2021, time=2021-04-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=953651, encodeId=f08895365176, content=写的不错, beContent=null, objectType=article, channel=null, level=null, likeNumber=77, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7c151583732, createdName=446993560, createdTime=Sat Apr 03 21:34:59 CST 2021, time=2021-04-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1301946, encodeId=0f781301946bb, content=<a href='/topic/show?id=b469109e41d' target=_blank style='color:#2F92EE;'>#lncRNA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=46, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10974, encryptionId=b469109e41d, topicName=lncRNA)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2317301, createdName=xzw113, createdTime=Sat Apr 03 15:52:37 CST 2021, time=2021-04-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1514486, encodeId=abc415144867b, content=<a href='/topic/show?id=1ae010211143' target=_blank style='color:#2F92EE;'>#髓性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=102111, encryptionId=1ae010211143, topicName=髓性)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ae8810654266, createdName=more is better!, createdTime=Sat Apr 03 15:52:37 CST 2021, time=2021-04-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1553765, encodeId=0da31553e6572, content=<a href='/topic/show?id=5d56130069b' target=_blank style='color:#2F92EE;'>#NPM1#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=46, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13006, encryptionId=5d56130069b, topicName=NPM1)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=778d36, createdName=柳叶一刀, createdTime=Sat Apr 03 15:52:37 CST 2021, time=2021-04-03, status=1, ipAttribution=)]
    2021-04-04 446993560

    棒棒哒

    0

  7. [GetPortalCommentsPageByObjectIdResponse(id=2005751, encodeId=64c42005e51b4, content=<a href='/topic/show?id=6ff1525e13' target=_blank style='color:#2F92EE;'>#CRN#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5257, encryptionId=6ff1525e13, topicName=CRN)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=35fc2500023, createdName=yanjie6253_56072842, createdTime=Fri Feb 25 03:52:37 CST 2022, time=2022-02-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2087964, encodeId=6b6e208e96406, content=<a href='/topic/show?id=490750196b' target=_blank style='color:#2F92EE;'>#COMMUN#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5019, encryptionId=490750196b, topicName=COMMUN)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7931272, createdName=liuli5079, createdTime=Sat Apr 10 05:52:37 CST 2021, time=2021-04-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1885082, encodeId=3d4918850825e, content=<a href='/topic/show?id=3b2112532d8' target=_blank style='color:#2F92EE;'>#Nat#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12532, encryptionId=3b2112532d8, topicName=Nat)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2e6f107, createdName=liye789132251, createdTime=Wed Mar 16 16:52:37 CST 2022, time=2022-03-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=953397, encodeId=5b1695339e43, content=lncRNA HOXBLINC的激活在NPM1c+白血病中起着重要的致癌作用。<a href='/topic/show?id=1991e1775c9' target=_blank style='color:#2F92EE;'>#白血病#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=160, replyNumber=1, topicName=null, topicId=null, topicList=[TopicDto(id=71775, encryptionId=1991e1775c9, topicName=白血病)], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210725/69b5882b3c3845c19efa131b4ff8b1f7/06ccd8f1857e4e14862049ab235618eb.jpg, createdBy=74c72110107, createdName=Nebula-Qin, createdTime=Fri Apr 02 23:14:07 CST 2021, time=2021-04-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1974523, encodeId=987a19e4523b5, content=<a href='/topic/show?id=e37b144015f' target=_blank style='color:#2F92EE;'>#PM1#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14401, encryptionId=e37b144015f, topicName=PM1)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d2f42500210, createdName=12498ef1m31(暂无昵称), createdTime=Thu Sep 09 13:52:37 CST 2021, time=2021-09-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=953781, encodeId=d646953e81df, content=棒棒哒, beContent=null, objectType=article, channel=null, level=null, likeNumber=73, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7c151583732, createdName=446993560, createdTime=Sun Apr 04 17:18:12 CST 2021, time=2021-04-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=953651, encodeId=f08895365176, content=写的不错, beContent=null, objectType=article, channel=null, level=null, likeNumber=77, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7c151583732, createdName=446993560, createdTime=Sat Apr 03 21:34:59 CST 2021, time=2021-04-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1301946, encodeId=0f781301946bb, content=<a href='/topic/show?id=b469109e41d' target=_blank style='color:#2F92EE;'>#lncRNA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=46, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10974, encryptionId=b469109e41d, topicName=lncRNA)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2317301, createdName=xzw113, createdTime=Sat Apr 03 15:52:37 CST 2021, time=2021-04-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1514486, encodeId=abc415144867b, content=<a href='/topic/show?id=1ae010211143' target=_blank style='color:#2F92EE;'>#髓性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=102111, encryptionId=1ae010211143, topicName=髓性)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ae8810654266, createdName=more is better!, createdTime=Sat Apr 03 15:52:37 CST 2021, time=2021-04-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1553765, encodeId=0da31553e6572, content=<a href='/topic/show?id=5d56130069b' target=_blank style='color:#2F92EE;'>#NPM1#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=46, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13006, encryptionId=5d56130069b, topicName=NPM1)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=778d36, createdName=柳叶一刀, createdTime=Sat Apr 03 15:52:37 CST 2021, time=2021-04-03, status=1, ipAttribution=)]
    2021-04-03 446993560

    写的不错

    0

  8. [GetPortalCommentsPageByObjectIdResponse(id=2005751, encodeId=64c42005e51b4, content=<a href='/topic/show?id=6ff1525e13' target=_blank style='color:#2F92EE;'>#CRN#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5257, encryptionId=6ff1525e13, topicName=CRN)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=35fc2500023, createdName=yanjie6253_56072842, createdTime=Fri Feb 25 03:52:37 CST 2022, time=2022-02-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2087964, encodeId=6b6e208e96406, content=<a href='/topic/show?id=490750196b' target=_blank style='color:#2F92EE;'>#COMMUN#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5019, encryptionId=490750196b, topicName=COMMUN)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7931272, createdName=liuli5079, createdTime=Sat Apr 10 05:52:37 CST 2021, time=2021-04-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1885082, encodeId=3d4918850825e, content=<a href='/topic/show?id=3b2112532d8' target=_blank style='color:#2F92EE;'>#Nat#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12532, encryptionId=3b2112532d8, topicName=Nat)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2e6f107, createdName=liye789132251, createdTime=Wed Mar 16 16:52:37 CST 2022, time=2022-03-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=953397, encodeId=5b1695339e43, content=lncRNA HOXBLINC的激活在NPM1c+白血病中起着重要的致癌作用。<a href='/topic/show?id=1991e1775c9' target=_blank style='color:#2F92EE;'>#白血病#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=160, replyNumber=1, topicName=null, topicId=null, topicList=[TopicDto(id=71775, encryptionId=1991e1775c9, topicName=白血病)], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210725/69b5882b3c3845c19efa131b4ff8b1f7/06ccd8f1857e4e14862049ab235618eb.jpg, createdBy=74c72110107, createdName=Nebula-Qin, createdTime=Fri Apr 02 23:14:07 CST 2021, time=2021-04-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1974523, encodeId=987a19e4523b5, content=<a href='/topic/show?id=e37b144015f' target=_blank style='color:#2F92EE;'>#PM1#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14401, encryptionId=e37b144015f, topicName=PM1)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d2f42500210, createdName=12498ef1m31(暂无昵称), createdTime=Thu Sep 09 13:52:37 CST 2021, time=2021-09-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=953781, encodeId=d646953e81df, content=棒棒哒, beContent=null, objectType=article, channel=null, level=null, likeNumber=73, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7c151583732, createdName=446993560, createdTime=Sun Apr 04 17:18:12 CST 2021, time=2021-04-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=953651, encodeId=f08895365176, content=写的不错, beContent=null, objectType=article, channel=null, level=null, likeNumber=77, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7c151583732, createdName=446993560, createdTime=Sat Apr 03 21:34:59 CST 2021, time=2021-04-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1301946, encodeId=0f781301946bb, content=<a href='/topic/show?id=b469109e41d' target=_blank style='color:#2F92EE;'>#lncRNA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=46, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10974, encryptionId=b469109e41d, topicName=lncRNA)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2317301, createdName=xzw113, createdTime=Sat Apr 03 15:52:37 CST 2021, time=2021-04-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1514486, encodeId=abc415144867b, content=<a href='/topic/show?id=1ae010211143' target=_blank style='color:#2F92EE;'>#髓性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=102111, encryptionId=1ae010211143, topicName=髓性)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ae8810654266, createdName=more is better!, createdTime=Sat Apr 03 15:52:37 CST 2021, time=2021-04-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1553765, encodeId=0da31553e6572, content=<a href='/topic/show?id=5d56130069b' target=_blank style='color:#2F92EE;'>#NPM1#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=46, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13006, encryptionId=5d56130069b, topicName=NPM1)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=778d36, createdName=柳叶一刀, createdTime=Sat Apr 03 15:52:37 CST 2021, time=2021-04-03, status=1, ipAttribution=)]
    2021-04-03 xzw113
  9. [GetPortalCommentsPageByObjectIdResponse(id=2005751, encodeId=64c42005e51b4, content=<a href='/topic/show?id=6ff1525e13' target=_blank style='color:#2F92EE;'>#CRN#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5257, encryptionId=6ff1525e13, topicName=CRN)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=35fc2500023, createdName=yanjie6253_56072842, createdTime=Fri Feb 25 03:52:37 CST 2022, time=2022-02-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2087964, encodeId=6b6e208e96406, content=<a href='/topic/show?id=490750196b' target=_blank style='color:#2F92EE;'>#COMMUN#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5019, encryptionId=490750196b, topicName=COMMUN)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7931272, createdName=liuli5079, createdTime=Sat Apr 10 05:52:37 CST 2021, time=2021-04-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1885082, encodeId=3d4918850825e, content=<a href='/topic/show?id=3b2112532d8' target=_blank style='color:#2F92EE;'>#Nat#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12532, encryptionId=3b2112532d8, topicName=Nat)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2e6f107, createdName=liye789132251, createdTime=Wed Mar 16 16:52:37 CST 2022, time=2022-03-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=953397, encodeId=5b1695339e43, content=lncRNA HOXBLINC的激活在NPM1c+白血病中起着重要的致癌作用。<a href='/topic/show?id=1991e1775c9' target=_blank style='color:#2F92EE;'>#白血病#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=160, replyNumber=1, topicName=null, topicId=null, topicList=[TopicDto(id=71775, encryptionId=1991e1775c9, topicName=白血病)], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210725/69b5882b3c3845c19efa131b4ff8b1f7/06ccd8f1857e4e14862049ab235618eb.jpg, createdBy=74c72110107, createdName=Nebula-Qin, createdTime=Fri Apr 02 23:14:07 CST 2021, time=2021-04-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1974523, encodeId=987a19e4523b5, content=<a href='/topic/show?id=e37b144015f' target=_blank style='color:#2F92EE;'>#PM1#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14401, encryptionId=e37b144015f, topicName=PM1)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d2f42500210, createdName=12498ef1m31(暂无昵称), createdTime=Thu Sep 09 13:52:37 CST 2021, time=2021-09-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=953781, encodeId=d646953e81df, content=棒棒哒, beContent=null, objectType=article, channel=null, level=null, likeNumber=73, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7c151583732, createdName=446993560, createdTime=Sun Apr 04 17:18:12 CST 2021, time=2021-04-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=953651, encodeId=f08895365176, content=写的不错, beContent=null, objectType=article, channel=null, level=null, likeNumber=77, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7c151583732, createdName=446993560, createdTime=Sat Apr 03 21:34:59 CST 2021, time=2021-04-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1301946, encodeId=0f781301946bb, content=<a href='/topic/show?id=b469109e41d' target=_blank style='color:#2F92EE;'>#lncRNA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=46, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10974, encryptionId=b469109e41d, topicName=lncRNA)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2317301, createdName=xzw113, createdTime=Sat Apr 03 15:52:37 CST 2021, time=2021-04-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1514486, encodeId=abc415144867b, content=<a href='/topic/show?id=1ae010211143' target=_blank style='color:#2F92EE;'>#髓性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=102111, encryptionId=1ae010211143, topicName=髓性)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ae8810654266, createdName=more is better!, createdTime=Sat Apr 03 15:52:37 CST 2021, time=2021-04-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1553765, encodeId=0da31553e6572, content=<a href='/topic/show?id=5d56130069b' target=_blank style='color:#2F92EE;'>#NPM1#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=46, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13006, encryptionId=5d56130069b, topicName=NPM1)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=778d36, createdName=柳叶一刀, createdTime=Sat Apr 03 15:52:37 CST 2021, time=2021-04-03, status=1, ipAttribution=)]
  10. [GetPortalCommentsPageByObjectIdResponse(id=2005751, encodeId=64c42005e51b4, content=<a href='/topic/show?id=6ff1525e13' target=_blank style='color:#2F92EE;'>#CRN#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5257, encryptionId=6ff1525e13, topicName=CRN)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=35fc2500023, createdName=yanjie6253_56072842, createdTime=Fri Feb 25 03:52:37 CST 2022, time=2022-02-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2087964, encodeId=6b6e208e96406, content=<a href='/topic/show?id=490750196b' target=_blank style='color:#2F92EE;'>#COMMUN#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5019, encryptionId=490750196b, topicName=COMMUN)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7931272, createdName=liuli5079, createdTime=Sat Apr 10 05:52:37 CST 2021, time=2021-04-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1885082, encodeId=3d4918850825e, content=<a href='/topic/show?id=3b2112532d8' target=_blank style='color:#2F92EE;'>#Nat#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12532, encryptionId=3b2112532d8, topicName=Nat)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2e6f107, createdName=liye789132251, createdTime=Wed Mar 16 16:52:37 CST 2022, time=2022-03-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=953397, encodeId=5b1695339e43, content=lncRNA HOXBLINC的激活在NPM1c+白血病中起着重要的致癌作用。<a href='/topic/show?id=1991e1775c9' target=_blank style='color:#2F92EE;'>#白血病#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=160, replyNumber=1, topicName=null, topicId=null, topicList=[TopicDto(id=71775, encryptionId=1991e1775c9, topicName=白血病)], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210725/69b5882b3c3845c19efa131b4ff8b1f7/06ccd8f1857e4e14862049ab235618eb.jpg, createdBy=74c72110107, createdName=Nebula-Qin, createdTime=Fri Apr 02 23:14:07 CST 2021, time=2021-04-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1974523, encodeId=987a19e4523b5, content=<a href='/topic/show?id=e37b144015f' target=_blank style='color:#2F92EE;'>#PM1#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14401, encryptionId=e37b144015f, topicName=PM1)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d2f42500210, createdName=12498ef1m31(暂无昵称), createdTime=Thu Sep 09 13:52:37 CST 2021, time=2021-09-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=953781, encodeId=d646953e81df, content=棒棒哒, beContent=null, objectType=article, channel=null, level=null, likeNumber=73, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7c151583732, createdName=446993560, createdTime=Sun Apr 04 17:18:12 CST 2021, time=2021-04-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=953651, encodeId=f08895365176, content=写的不错, beContent=null, objectType=article, channel=null, level=null, likeNumber=77, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7c151583732, createdName=446993560, createdTime=Sat Apr 03 21:34:59 CST 2021, time=2021-04-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1301946, encodeId=0f781301946bb, content=<a href='/topic/show?id=b469109e41d' target=_blank style='color:#2F92EE;'>#lncRNA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=46, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10974, encryptionId=b469109e41d, topicName=lncRNA)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2317301, createdName=xzw113, createdTime=Sat Apr 03 15:52:37 CST 2021, time=2021-04-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1514486, encodeId=abc415144867b, content=<a href='/topic/show?id=1ae010211143' target=_blank style='color:#2F92EE;'>#髓性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=102111, encryptionId=1ae010211143, topicName=髓性)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ae8810654266, createdName=more is better!, createdTime=Sat Apr 03 15:52:37 CST 2021, time=2021-04-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1553765, encodeId=0da31553e6572, content=<a href='/topic/show?id=5d56130069b' target=_blank style='color:#2F92EE;'>#NPM1#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=46, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13006, encryptionId=5d56130069b, topicName=NPM1)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=778d36, createdName=柳叶一刀, createdTime=Sat Apr 03 15:52:37 CST 2021, time=2021-04-03, status=1, ipAttribution=)]
    2021-04-03 柳叶一刀

相关资讯

CC-486治疗急性髓性白血病:FDA授予优先审查权

百时美施贵宝(Bristol Myers Squibb)近日表示,FDA授予了CC-486治疗成人急性髓性白血病(AML)的优先审查权。

FLT3抑制剂gilteritinib,获得英国NICE推荐治疗急性髓性白血病

接受gilteritinib治疗的患者中位总生存期为9.3个月,而接受化疗的患者为5.6个月,一年生存率分别为37%和17%。

Blood:定量蛋白质组学揭示AML干细胞的独特代谢特征

高分辨率蛋白质组学可明确与健康的HSPC相比经过功能验证的LSC中活跃的特征性通路和可靶向通路;代谢途径的改变主要表现在蛋白质上,在转录本水平上并不明显,这突出了蛋白质组学分析的优势。

Nat Commun:BRD4介导p53抑制作用是急性髓性白血病的联合治疗靶标

急性髓性白血病(AML)是一种典型的致死性分子异质性疾病,目前几乎没有针对该疾病的广谱的治疗靶标。

Blood:新型CRBN E3连接酶调节剂CC-90009,靶向促进白血病干细胞凋亡

在该研究中,Christine等鉴定了一种一流的GSPT1选择性脑蛋白E3连接酶调节剂CC-90009。

Cell Death Dis:lncRNA HOXA-AS2通过结合EZH2并抑制LATS2以促进AML发生发展

急性髓性白血病(AML)是全球最常见的血液系统恶性肿瘤,其两个主要特征是恶性增殖不受控制以及分化受阻,约占白血病相关死亡的30%。随着科学技术的发展,白血病的治疗取得了长足的进步,但该病的治愈方法仍未